Molecular Analysis of Endoscopic Cytology Samples Supernatant in Pulmonary Nodules
Recruiting
N/A
Interventional Study
Lung Cancer
Lung; Node
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 60 (estimated)
- Sponsor
- University Hospital, Toulouse · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Lung cancer screening is based on low dose CT scan (LDCT), a highly sensitive but poorly specific tool.
Complementary specific approaches are thus strongly needed, among which cell-free DNA (cfDNA) genotyping has been proven highly specific but of low sensitivity (25 to 50% for stage I diseases) due to inconstant tumor shed. Tumor biopsy is thus often required and radial endobronchial ultrasound …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* rEBUS bronchoscopy planned for one, two or three ≤ 20 mm nodule
* World Health Organization (WHO) Performance status 0-3
* Informed signed consent
* Patient affiliated or beneficiary of a social security scheme (Social Security or Universal Medical Coverage).
Exclusion Criter…
Contacts